June 2022 FDA Recall Asprin And Extended-release Dipyridamole by Glenmark Pharmaceuticals Inc., Usa
D-1282-2022 - Failed Tablet/Capsule Specification

This Class III drug recall was voluntarily initiated by Glenmark Pharmaceuticals Inc., Usa on June 29, 2022 for the product Asprin And Extended-release Dipyridamole. The FDA reported the reason for recall as failed tablet/capsule specification. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-1282-2022

Reason for Recall
Failed Tablet/Capsule Specification : Capsule breakage
Initiated
06-29-2022
Reported
07-27-2022
Quantity
168936 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Glenmark Pharmaceuticals Inc., USA
Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60.

Batch or Lot Expiration Information

Lot# : 17201639, Exp 08/2022; 17201759, Exp 09/2022; 17202067, Exp 10/2022; 17210696, Exp 02/2023; 17210092, Exp 11/2022; 17210145, Exp 12/2022; 17210732, Exp 02/2023; 17211062, Exp 04/2023; 17211441, Exp 05/2023; 17211670, Exp 06/2023; 17211810, Exp 07/2023; 17211862, 17212020, 17212068, Exp 08/2023; 17212438, Exp 10/2023; 17220172, 17220251, Exp 12/2023.